Bullish Case: INTU rebounded 21.6% in a month to $344.72, aided by the Sequence acquisition and reaffirmed FY27 guidance ($23.28-23.51B, 9-10% growth). Helium's bullish risk is 25% above bearish risk, and the return surface concentrates mass near small positive moves. AI-workflow adoption and margin expansion to ~24.8% by 2029 offer re-rate optionality if the recovery holds above $340.

Bearish Case: The IV term structure is sharply backwardated (Nov 7 ~62-85% vs ~51% mid-2027) and Helium's forecast is -2.62%, signaling near-term event fear despite the rally. Puts traded 17% more volume, price is still -47.7% year-over-year, and the 80% short-dated IV spike warns the bounce may exhaust; a stall below $350 reopens $315-330.

Potential Outcomes:

1. 35%: Consolidation $335-365 as backwardated IV decays after Nov 7; falsified if price holds >$365 into Dec.
2. 25%: Continuation to $365-385 on AI/SimpleClosure adoption news and 90-day momentum (volume caveat: 0th percentile).
3. 25%: Pullback $310-335 as the -2.62% Helium signal and put skew reassert; SPY risk-off accelerates it.
4. 10%: Drop <$300 if a guidance cut or macro shock hits; backwardation + high short-dated IV supports this tail.
5. 5%: >$400 rerate on beat; low conviction given flat recent action.

November 04, 2026